Oncology
Clear Cell Carcinoma
0
Pipeline Programs↗
6
Active Trials↗
2
Companies Involved↗
Clear Cell Carcinoma is an early-stage landscape with 0 programs across 2 companies. The most active players are Telix Pharmaceuticals (Innovations) Pty Limited, Haihe Biopharma Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
9
clinical trials
Recruiting4 · 44%
Completed2 · 22%
Active, not recruiting2 · 22%
Unknown status1 · 11%
Clinical Trials
Trial Activity
9 trials
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Recruiting·—·Phase 2·NCT06677190·32 enrolled
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Active, not recruiting·—·Phase 2·NCT03355976·46 enrolled
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Completed·—·Phase 2·NCT00853021·26 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)